HT
HTD.F Corcept Therapeutics Incorporated
- Market cap
- EUR 7.29B
- P/E
- 58.4x
- P/B
- 9.44x
- ROE
- 22.1%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is HTD.F undervalued?
Graham numberThe Graham number of Corcept Therapeutics Incorporated cannot be estimated reliably (the estimate is too far from the market price).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Corcept Therapeutics Incorporated fundamental analysis
No fundamental analysis for Corcept Therapeutics Incorporated yet.
Corcept Therapeutics Incorporated stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Corcept Therapeutics Incorporated
Corcept Therapeutics Incorporated, a biopharmaceutical company, engages in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. The company offers Korlym, an oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not ca…
Full company profileCorcept Therapeutics Incorporated financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Corcept Therapeutics Incorporated annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 81.3M | 159M | 251M | 306M | 354M | 366M | 402M | 482M | 675M | 761M | 1.02B |
| Gross Profit | 79.3M | 156M | 246M | 301M | 348M | 361M | 396M | 476M | 664M | 748M | 1,000M |
| Operating Income | 10.2M | 52.9M | 89.5M | 112M | 128M | 124M | 113M | 107M | 137M | 44.8M | 142M |
| EBITDA | - | 53.0M | 89.7M | 114M | 130M | 128M | 116M | - | - | - | 145M |
| Net Income | 8.14M | 129M | 75.4M | 94.2M | 106M | 113M | 101M | 106M | 141M | 99.7M | 184M |
| EPS | - | 1.13 | 0.66 | 0.82 | 0.91 | 1.06 | 0.94 | 1.03 | 1.34 | 0.94 | 1.70 |
| Balance Sheet | |||||||||||
| Total Assets | 68.8M | 221M | 312M | 412M | 572M | 424M | 583M | 622M | 841M | 837M | 1.03B |
| Total Liabilities | 27.4M | 29.6M | 35.8M | 41.1M | 48.4M | 48.0M | 81.6M | 115M | 161M | 189M | 200M |
| Shareholders' Equity | 41.4M | 191M | 276M | 371M | 523M | 376M | 502M | 507M | 680M | 648M | 834M |
| Cash & Short-term Investments | 51.5M | 31.1M | 41.6M | 31.3M | 76.2M | 77.6M | 437M | 136M | 128M | 120M | 98.7M |
| Cash Flow | |||||||||||
| Operating Cash Flow | 18.4M | 60.9M | 116M | 136M | 152M | 168M | 120M | 155M | 198M | 142M | 213M |
| Capital Expenditure | 194K | 419K | 298K | 1.09M | 1.24M | 469K | 413K | 170K | 2.17M | 211K | 4.58M |
| Free Cash Flow | - | 60.5M | 115M | 135M | 151M | 167M | 120M | 154M | 196M | 142M | 208M |
| Ratios | |||||||||||
| ROE | 19.7% | 67.6% | 27.3% | 25.4% | 20.3% | 29.9% | 20.2% | 20.9% | 20.8% | 15.4% | 22.1% |
| ROA | 11.8% | 58.5% | 24.2% | 22.8% | 18.5% | 26.6% | 17.4% | 17.1% | 16.8% | 11.9% | 17.8% |
| Net Profit Margin | 10.0% | 81.1% | 30.0% | 30.7% | 30.0% | 30.7% | 25.2% | 22.0% | 20.9% | 13.1% | 18.1% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Corcept Therapeutics Incorporated dividends
Corcept Therapeutics Incorporated has not paid dividends in the last 9 fiscal years.
Who owns Corcept Therapeutics Incorporated
- Insiders 11.32%
- Institutions 75.47%
- Public & others 13.20%
- Shares outstanding 109M
- Free float 97.8M
Corcept Therapeutics Incorporated company profile
- Company name
- Corcept Therapeutics Incorporated
- Ticker
- HTD.F
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 730
- Fiscal year end
- December
- Address
- 101 Redwood Shores Parkway, Redwood City, CA, United States, 94065
- Phone
- 650 327 3270
- Website
- corcept.com
About Corcept Therapeutics Incorporated
Corcept Therapeutics Incorporated, a biopharmaceutical company, engages in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. The company offers Korlym, an oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. It also develops relacorilant, a selective cortisol modulator for patients with hypercortisolism; a selective cortisol modulator miricorilant, which is in Phase 1b trial for metabolic dysfunction-associated steatohepatitis; and a portfolio of proprietary selective cortisol modulators, such as relacorilant, nenocorilant, miricorilant, and dazucorilant for the treatment of Lou Gehrig's disease. The company was incorporated in 1998 and is headquartered in Redwood City, California.
Corcept Therapeutics Incorporated management
10- Dr. Joseph K. Belanoff M.D.Co-Founder, President, CEO & Director · born 1957
- Mr. Atabak MokariCFO & Treasurer · born 1977
- Dr. William Guyer Pharm.D.Chief Development Officer · born 1968
- Mr. Gary Charles Robb J.D.Chief Business Officer & Secretary · born 1963
- Mr. Joseph Douglas LyonChief Technology & Accounting Officer · born 1978
- Dr. Hazel Hunt Ph.D.Chief Scientific Officer · born 1960
- Ms. Amy FloodChief Human Resources & Communications Officer
- Ms. Monica TelladoPresident of Emerging Markets · born 1973
- Mr. Roberto W. VieiraPresident of Oncology
- Mr. Justin Gunn M.D.President of Endocrinology